Results 41 to 50 of about 774,384 (405)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]

, 2017
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core   +2 more sources

Methotrexate and rheumatoid arthritis associated interstitial lung disease

European Respiratory Journal, 2020
Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of RA.
P. Juge, Joyce S. Lee, J. Lau, Letícia Kawano-Dourado, J. Serrano, M. Sebastiani, G. Koduri, E. Matteson, K. Bonfiglioli, M. Sawamura, R. Kairalla, L. Cavagna, E. B. Cassione, A. Manfredi, M. Mejía, P. Rodríguez-Henríquez, M. González-Pérez, R. Falfán-Valencia, I. Buendía-Roldán, G. Pérez-Rubio, E. Ebstein, S. Gazal, S. Gazal, R. Borie, S. Ottaviani, C. Kannengiesser, B. Wallaert, Y. Uzunhan, H. Nunes, D. Valeyre, N. Saidenberg-Kermanac’h, M. Boissier, L. Wémeau-Stervinou, R. Flipo, S. Marchand-Adam, P. Richette, P. Richette, Y. Allanore, Y. Allanore, C. Dromer, M. Truchetet, C. Richez, T. Schaeverbeke, H. Lioté, G. Thabut, K. Deane, J. Solomon, T. Doyle, J. Ryu, I. Rosas, V. Holers, C. Boileau, M. Debray, R. Porcher, D. Schwartz, R. Vassallo, B. Crestani, P. Dieudé   +57 more
semanticscholar   +1 more source

Idiopathic pleuroparenchymal fibroelastosis (PPFE) – A case study of a rare entity

Revista Portuguesa de Pneumologia (English Edition), 2017
Idiopathic pleuroparenchymal fibroelastosis (IPPFE) was recognized as a rare new entity. We report the case of a 63 years old female suffering from progressive dyspnea and dry cough for three years.
E.B. Boerner, U. Costabel, T.E. Wessendorf, D. Theegarten, F. Bonella   +4 more
doaj   +1 more source

Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused

Frontiers in Medicine, 2020
After decades of research, two therapies for chronic fibrotic lung disease are now approved by the FDA, with dozens more anti-fibrotic therapies in the pipeline.
Sachin Chaudhary, Bhupinder Natt, Christian Bime, Kenneth S. Knox, Kenneth S. Knox, Marilyn K. Glassberg   +5 more
doaj   +1 more source

Immune mechanisms in fibrotic pulmonary sarcoidosis

European Respiratory Review, 2022
Sarcoidosis is an immune-mediated disorder. Its immunopathology has been steadily mapped out over the past few decades. Despite this, the underpinning mechanisms for progressive fibrotic sarcoidosis is an almost uncharted area.
Praveen Weeratunga, David R. Moller, Ling-Pei Ho   +2 more
doaj   +1 more source

Amiodarone-Induced Pulmonary Toxicity - A Frequently Missed Complication. [PDF]

, 2016
IntroductionAmiodarone is often used in the suppression of tachyarrhythmias. One of the more serious adverse effects includes amiodarone pulmonary toxicity (APT).
Dang, Natasha, Datta, Jyoti, Lam, Vinh, Singh, Navneet K, Sweidan, Alexander J   +4 more
core   +2 more sources

Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults

BMC Pulmonary Medicine, 2019
Background Diffuse alveolar haemorrhage (DAH) is characterized by the diffuse accumulation of red blood cells within the alveoli, presence of ground glass opacities and/or consolidation on computed tomography (CT).
Anna Stainer, Alex Rice, Anand Devaraj, Joseph Luke Barnett, Jacqueline Donovan, Maria Kokosi, Andrew Gordon Nicholson, Tom Cairns, Athol Umfrey Wells, Elisabetta Augusta Renzoni   +9 more
doaj   +1 more source

Prognostic factors in chronic hypersensitivity pneumonitis

European Respiratory Review, 2020
Hypersensitivity pneumonitis (HP) is an immunologically mediated lung disease resulting from exposure to inhaled environmental antigens. Prognosis is variable, with a subset of patients developing progressive fibrosis leading to respiratory failure and ...
Andrew W. Creamer, Shaney L. Barratt
doaj   +1 more source

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Annals of the Rheumatic Diseases, 2020
Objectives To identify overall disease course, progression patterns and risk factors predictive for progressive interstitial lung disease (ILD) in patients with systemic sclerosis-associated ILD (SSc-ILD), using data from the European Scleroderma Trials ...
A. Hoffmann-Vold, Y. Allanore, M. Alves, C. Brunborg, P. Airó, L. Ananieva, L. Czirják, S. Guiducci, E. Hachulla, Mengtao Li, C. Mihai, G. Riemekasten, P. Sfikakis, O. Kowal-Bielecka, A. Riccardi, O. Distler   +15 more
semanticscholar   +1 more source

Increased expression of 5-hydroxytryptamine(2A/B) receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention [PDF]

, 2010
Background Idiopathic pulmonary fibrosis (IPF) has a poor prognosis and limited responsiveness to available treatments. It is characterised by epithelial cell injury, fibroblast activation and proliferation and extracellular matrix deposition ...
Amarie, Oana Veronica, Dumitrascu, Rio, Eickelberg, Oliver, Grimminger, Friedrich, Königshoff, Melanie, Reiter, Rudolf, Schermuly, Ralph Theo, Seeger, Werner, Udalov, Sergey   +8 more
core   +1 more source